PT2608789T - Usos terapêuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina - Google Patents

Usos terapêuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina

Info

Publication number
PT2608789T
PT2608789T PT117493312T PT11749331T PT2608789T PT 2608789 T PT2608789 T PT 2608789T PT 117493312 T PT117493312 T PT 117493312T PT 11749331 T PT11749331 T PT 11749331T PT 2608789 T PT2608789 T PT 2608789T
Authority
PT
Portugal
Prior art keywords
phenylsulfanyl
piperazine
dimethyl
phenyl
therapeutic uses
Prior art date
Application number
PT117493312T
Other languages
English (en)
Portuguese (pt)
Inventor
Dragheim Marianne
Florea Ioana
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2608789(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PT2608789T publication Critical patent/PT2608789T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT117493312T 2010-08-23 2011-08-22 Usos terapêuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina PT2608789T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37588510P 2010-08-23 2010-08-23
DKPA201000739 2010-08-23

Publications (1)

Publication Number Publication Date
PT2608789T true PT2608789T (pt) 2017-05-26

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117493312T PT2608789T (pt) 2010-08-23 2011-08-22 Usos terapêuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina

Country Status (32)

Country Link
US (5) US20130184291A1 (enExample)
EP (1) EP2608789B2 (enExample)
JP (1) JP5902169B2 (enExample)
KR (1) KR101816953B1 (enExample)
CN (1) CN103068389A (enExample)
AP (1) AP3583A (enExample)
AR (1) AR082501A1 (enExample)
AU (1) AU2011295465B8 (enExample)
BR (2) BR122020025600A2 (enExample)
CA (1) CA2807062C (enExample)
CL (1) CL2013000492A1 (enExample)
CO (1) CO6680652A2 (enExample)
CY (1) CY1118886T1 (enExample)
DK (1) DK2608789T4 (enExample)
ES (1) ES2625142T5 (enExample)
FI (1) FI2608789T4 (enExample)
HR (1) HRP20170608T4 (enExample)
HU (1) HUE034155T2 (enExample)
IL (1) IL224371A (enExample)
LT (1) LT2608789T (enExample)
ME (1) ME02674B (enExample)
MX (1) MX349724B (enExample)
PL (1) PL2608789T5 (enExample)
PT (1) PT2608789T (enExample)
RS (1) RS55851B2 (enExample)
RU (1) RU2564666C2 (enExample)
SG (1) SG187649A1 (enExample)
SI (1) SI2608789T2 (enExample)
SM (1) SMT201700239T1 (enExample)
TW (1) TW201212918A (enExample)
WO (1) WO2012025123A1 (enExample)
ZA (1) ZA201301385B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
ES2087463T3 (es) * 1991-11-18 1996-07-16 Lilly Industries Ltd Benzo(b)tiofen-2-carboxamidas para el tratamiento de trastornos del sistema nervioso central.
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
WO2002029232A1 (en) 2000-10-02 2002-04-11 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
HUE034155T2 (en) 2018-01-29
BR122020025600A2 (pt) 2021-01-05
US20190000836A1 (en) 2019-01-03
KR20130097162A (ko) 2013-09-02
JP5902169B2 (ja) 2016-04-13
AU2011295465A1 (en) 2013-02-07
JP2013536206A (ja) 2013-09-19
RS55851B1 (sr) 2017-08-31
RU2013112890A (ru) 2014-09-27
SI2608789T2 (sl) 2025-05-30
RS55851B2 (sr) 2024-11-29
TW201212918A (en) 2012-04-01
PL2608789T5 (pl) 2025-11-12
HRP20170608T4 (hr) 2024-12-06
DK2608789T4 (da) 2024-11-04
US20220370439A1 (en) 2022-11-24
ES2625142T5 (en) 2025-02-10
LT2608789T (lt) 2017-05-25
ZA201301385B (en) 2014-04-30
AU2011295465B2 (en) 2014-06-19
IL224371A (en) 2016-07-31
CL2013000492A1 (es) 2013-06-07
MX2013001570A (es) 2013-03-21
RU2564666C2 (ru) 2015-10-10
WO2012025123A1 (en) 2012-03-01
KR101816953B1 (ko) 2018-01-09
PL2608789T3 (pl) 2017-09-29
CN103068389A (zh) 2013-04-24
EP2608789A1 (en) 2013-07-03
US20130184291A1 (en) 2013-07-18
EP2608789B2 (en) 2024-08-21
SI2608789T1 (sl) 2017-06-30
SG187649A1 (en) 2013-03-28
AP2013006768A0 (en) 2012-03-31
AP3583A (en) 2016-02-09
US20210085674A1 (en) 2021-03-25
DK2608789T3 (en) 2017-05-15
SMT201700239T1 (it) 2017-07-18
CO6680652A2 (es) 2013-05-31
AR082501A1 (es) 2012-12-12
ES2625142T3 (es) 2017-07-18
CY1118886T1 (el) 2018-01-10
FI2608789T4 (fi) 2024-11-01
MX349724B (es) 2017-08-10
HRP20170608T1 (hr) 2017-07-28
CA2807062C (en) 2018-07-31
AU2011295465B8 (en) 2014-07-10
CA2807062A1 (en) 2012-03-01
US20240293397A1 (en) 2024-09-05
EP2608789B1 (en) 2017-04-12
ME02674B (me) 2017-06-20
BR112013002194A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
SG173735A1 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
ZA201107731B (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
IL246600B (en) Heterocyclic compounds and their use
CO7000771A2 (es) Proceso para la fabricación de 1-[2-(2,4-dimetilsulfanil)fenil]piperazina
PL2521450T3 (pl) Grzybobójcze związki heterocykliczne
IL225770A0 (en) Heterocyclic compounds
EP2643000A4 (en) THERAPEUTIC PIPERAZINES
EP2637669A4 (en) Heterocyclic compounds and their use
ZA201201360B (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
EP2656872A4 (en) ELECTRODE PAD FOR IONTOPHORESIS
AP2013006987A0 (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
IL213917A0 (en) Novel compounds for medical use as peptidase effectors
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
ZA201205879B (en) Piperazines as antimalarial agents
GB201019043D0 (en) Use of 2',5'-oligoadenylate derivative compounds
AU2012900131A0 (en) "Heterocyclic compounds"
PL393335A1 (pl) Nowe E-1,2-bis{4-[(2-(1-oxo-alkilo)-3-oxo-alkilo]fenylo) eteny oraz sposób ich otrzymywania
GB201009514D0 (en) Novel heterocyclic compounds
GB201021416D0 (en) Novel heterocyclic compounds
GB201001364D0 (en) New compounds and medical uses
GB201001370D0 (en) New compounds and medical uses
GB201101823D0 (en) Novel heterocyclic compounds 4
GB201101822D0 (en) Novel heterocyclic compounds 2
GB201102024D0 (en) Novel heterocyclic compounds 3
GB201101821D0 (en) Novel heterocyclic compounds 1